Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005795 · ClinicalTrials.gov registry record · Phase 2
Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00005795 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 11 participants.
The verdict
NCT00005795, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have acute myeloid leukemia.
Interventions
- DRUG arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2000-02 |
| Est. Completion | 2002-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005795
The ClinicalTrials.gov registry entry for NCT00005795 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which arsenic trioxide is the first listed.
NCT00005795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005795 about?
NCT00005795 is a clinical study titled "Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have acute myeloid leukemia.
What is the current status of trial NCT00005795?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2000-02. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00005795?
The interventions under investigation include: arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT00005795?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.